Effect of psilocin on extracellular dopamine and serotonin levels in the mesoaccumbens and mesocortical pathway in awake rats.

Psilocin (3-[2-(dimethylamino)ethyl]-1H-indol-4-ol) is a hallucinogenic component of the Mexican mushroom Psilocybe mexicana and a skeletal serotonin (5-HT) analogue. Psilocin is the active metabolite of psilocybin (3-[2-(dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate). In the present study, we examined the effects of systemically administered psilocin on extracellular dopamine and 5-HT concentrations in the ventral tegmental area (VTA), nucleus accumbens, and medial prefrontal cortex of the dopaminergic pathway in awake rats using in vivo microdialysis. Intraperitoneal administration of psilocin (5, 10 mg/kg) significantly increased extracellular dopamine levels in the nucleus accumbens. Psilocin did not affect the extracellular 5-HT level in the nucleus accumbens. Conversely, systemic administration of psilocin (10 mg/kg) significantly increased extracellular 5-HT levels in the medial prefrontal cortex of rats, but dopamine was decreased in this region. However, neither extracellular dopamine nor 5-HT levels in the VTA were altered by administration of psilocin. Behaviorally, psilocin significantly increased the number of head twitches. Thus, psilocin affects the dopaminergic system in the nucleus accumbens. In the serotonergic system, psilocin contribute to a crucial effect in the medial prefrontal cortex. The present data suggest that psilocin increased both the extracellular dopamine and 5-HT concentrations in the mesoaccumbens and/or mesocortical pathway.

[1]  Jordi Serrats,et al.  Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. , 2004, Cerebral cortex.

[2]  T. Svensson,et al.  Involvement of 5‐HT2A receptor and α2‐adrenoceptor blockade in the asenapine‐induced elevation of prefrontal cortical monoamine outflow , 2012, Synapse.

[3]  L. Parsons,et al.  Serotonin and Dopamine Sensitization in the Nucleus Accumbens, Ventral Tegmental Area, and Dorsal Raphe Nucleus Following Repeated Cocaine Administration , 1993, Journal of neurochemistry.

[4]  M. Galloway,et al.  Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. , 1991, European journal of pharmacology.

[5]  S. Kapur,et al.  Serotonin-dopamine interaction and its relevance to schizophrenia. , 1996, The American journal of psychiatry.

[6]  J. C. Winter,et al.  Psilocybin-induced stimulus control in the rat , 2007, Pharmacology Biochemistry and Behavior.

[7]  C. Grob,et al.  Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. , 2011, Archives of general psychiatry.

[8]  Franz X Vollenweider,et al.  The Effects of the Preferential 5-HT2A Agonist Psilocybin on Prepulse Inhibition of Startle in Healthy Human Volunteers Depend on Interstimulus Interval , 2007, Neuropsychopharmacology.

[9]  M. Millan,et al.  The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways , 2003, Journal of Pharmacology and Experimental Therapeutics.

[10]  W. Mcbride,et al.  Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release , 1989, Brain Research Bulletin.

[11]  Felix Hasler,et al.  Modulating the Rate and Rhythmicity of Perceptual Rivalry Alternations with the Mixed 5-HT2A and 5-HT1A Agonist Psilocybin , 2005, Neuropsychopharmacology.

[12]  R. Griffiths,et al.  Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance , 2006, Psychopharmacology.

[13]  F. Vollenweider,et al.  Positron Emission Tomography and Fluorodeoxyglucose Studies of Metabolic Hyperfrontality and Psychopathology in the Psilocybin Model of Psychosis , 1997, Neuropsychopharmacology.

[14]  Felix Hasler,et al.  Effects of psilocybin on time perception and temporal control of behaviour in humans , 2007, Journal of psychopharmacology.

[15]  Peter Vontobel,et al.  5-HT Modulation of Dopamine Release in Basal Ganglia in Psilocybin-Induced Psychosis in Man—A PET Study with [11C]raclopride , 1999, Neuropsychopharmacology.

[16]  M. Pompeiano,et al.  Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. , 1994, Brain research. Molecular brain research.

[17]  F. Vollenweider,et al.  Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. , 1997, Pharmaceutica acta Helvetiae.

[18]  F. Vollenweider,et al.  Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man. , 2002, Journal of pharmaceutical and biomedical analysis.

[19]  Felix Hasler,et al.  Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans , 2007, Psychopharmacology.

[20]  J. Micó,et al.  Role of atypical opiates in OCD. Experimental approach through the study of 5-HT2A/C receptor-mediated behavior , 2006, Psychopharmacology.

[21]  J. Joyce.  The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine , 2005, Psychopharmacology.

[22]  D. E. Nichols,et al.  Effect of Ring Fluorination on the Pharmacology of Hallucinogenic Tryptamines. , 2001 .

[23]  P. Delgado,et al.  Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. , 2006, The Journal of clinical psychiatry.

[24]  M. Geyer,et al.  Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans , 1998, Behavioural pharmacology.

[25]  B. Roth,et al.  SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. , 2005, Bioorganic & Medicinal Chemistry Letters.

[26]  M. Geyer,et al.  Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice , 2011, Journal of psychopharmacology.

[27]  L. Pozzi,et al.  Stimulation of 5‐hydroxytryptamine (5‐HT2C) receptors in the ventrotegmental area inhibits stress‐induced but not basal dopamine release in the rat prefrontal cortex , 2002, Journal of neurochemistry.

[28]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[29]  H. Hojo,et al.  Preparation of Monoclonal Antibodies Reactive to a Hallucinogenic Drug, Psilocin , 2004 .

[30]  Andreas Bäbler,et al.  Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action , 1998, Neuroreport.

[31]  E. Pehek,et al.  Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. , 2007, Pharmacology & therapeutics.

[32]  H. Isbell,et al.  Comparison of psilocin with psilocybin, mescaline and LSD-25 , 2004, Psychopharmacologia.

[33]  M. Geyer,et al.  Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers , 2012, Neuropsychopharmacology.